Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.

This is written in the approval document as:

Treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.

Reimbursement

Hospital

Citation

R-CEOP Therapy - 21 days, 2026, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6614/510_R-CEOP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Non-Hodgkin Lymphoma	Cyclophosphamide, Etoposide, Prednisolone, Rituximab, Vincristine

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2019-01-29	Health Service Executive	Indication approved for reimbursement.